IceCure Successfully Completes First Cryoablation Treatment in Its ChoICE Post-Marketing Study for Breast Cancer Cryoablation

IceCure treated its first U.S. ChoICE Study patient, aiming for 400 total across 30 sites.

What the company is saying

IceCure Medical Ltd. is announcing the completion of the first patient treatment in its U.S. post-marketing ChoICE Study for ProSense® cryoablation in low-risk breast cancer. The company frames this as a milestone, emphasizing that the study is designed to enroll approximately 400 patients at up to 30 U.S. clinical sites. Management, including CEO Eyal Shamir and Dr. Richard E. Fine, highlight the expectation that this study will generate additional clinical data and support broader clinical adoption of ProSense®. The company stresses that participating sites will also serve as commercial centers, potentially expanding access to ProSense® beyond the study population. The announcement repeatedly references the FDA-cleared indication for ProSense®—specifically, its use in patients aged 70 and older with low-risk tumors ≤1.5 cm treated with adjuvant endocrine therapy. The tone is confident and forward-looking, focusing on the strategic importance of this first treatment and the anticipated impact on U.S. market penetration.

What the data suggests

The only realised operational milestone is the treatment of the first patient in the ChoICE Study at West Cancer Center in Tennessee. The study's design is clearly defined: approximately 400 patients across up to 30 U.S. clinical sites. No interim clinical efficacy or safety data are disclosed, nor are there any financial figures such as revenue, cash flow, or cost structure. The FDA clearance for ProSense® is limited to patients aged 70 and older with low-risk tumors ≤1.5 cm who are treated with adjuvant endocrine therapy, including those not eligible for surgery. The announcement confirms that ProSense® is marketed and sold worldwide for approved indications, but provides no data on U.S. sales or adoption. The evidence supports that the study has begun, but all claims about broader adoption, commercial impact, or clinical benefit remain unsubstantiated at this stage. The disclosure is adequate for a clinical milestone but insufficient for assessing financial or commercial progress.

Analysis

The announcement highlights the successful treatment of the first patient in the ChoICE Study, which is a concrete and realised milestone. However, the majority of the claims and narrative focus on forward-looking outcomes, such as enrolling 400 patients, generating real-world data, and expanding commercial adoption. The language used by management and investigators emphasizes the potential for broader clinical adoption and commercial expansion, but no interim efficacy, safety, or financial data are disclosed. The study is capital intensive, involving up to 30 sites and 400 patients, yet the benefits (clinical data, commercial impact) are long-term and uncertain. The gap between the company's positive tone and the actual evidence is moderate: while the first-patient milestone is real, most benefits are projected and contingent on future enrollment and data. No profitability or revenue metrics are provided, so the signal cannot be stronger than weak_positive.

Risk flags

• ●Execution risk is high, as enrolling approximately 400 patients across up to 30 U.S. clinical sites is a complex, lengthy, and resource-intensive process. Delays or enrollment shortfalls could undermine both clinical and commercial objectives.
• ●Commercial adoption risk remains significant, since the FDA-cleared indication is narrowly defined (patients aged 70+ with low-risk tumors ≤1.5 cm on adjuvant endocrine therapy), limiting the initial addressable market. Broader uptake will depend on future data and possible label expansion.
• ●Disclosure risk is present, as the announcement provides no interim efficacy, safety, or financial data. Investors have no visibility into early clinical outcomes or commercial traction, making it difficult to assess the likelihood of future success.

Bottom line

IceCure Medical has taken the first concrete step in its U.S. post-marketing ChoICE Study by treating the initial patient, but this is only the start of a lengthy process targeting 400 patients at up to 30 sites. The company’s messaging is optimistic and positions this as a strategic advance, yet no clinical or commercial results are available to validate the narrative. The FDA-cleared indication is narrow, so the immediate commercial opportunity is limited until further data support broader use. Investors should recognize that the primary value from this study will not materialize in the near term, and the main risks are slow enrollment, limited market scope, and lack of interim data. The most important takeaway is that while the study is underway, tangible evidence of clinical or commercial success is still absent; future updates must provide measurable results to change the investment case.

Announcement summary

(NASDAQ:ICCM) IceCure Medical Ltd. announced the successful completion of the first patient treatment in its post-marketing ChoICE Study evaluating ProSense® cryoablation for the local treatment of low-risk breast cancer. The first patient was treated at West Cancer Center & Research Institute in Germantown, Tennessee by Dr. Richard E. Fine, MD, FACS, who is a board-certified breast oncology surgeon and Director of the Breast Surgical Oncology Fellowship Program. The ChoICE Study is designed to enroll approximately 400 patients across up to 30 U.S. clinical sites. The study aims to generate real-world data on ProSense® in its U.S. Food and Drug Administration (FDA) cleared indication. Participating sites are expected to serve both as study centers and as active commercial sites, enabling them to offer ProSense® cryoablation to eligible patients who are not participating in the ChoICE Study. ProSense® cryoablation is the first and only medical device cleared by the FDA for the local treatment of breast cancer in patients aged 70 years and older with biologically low-risk tumors ≤1.5 cm in size who are treated with adjuvant endocrine therapy, including patients who are not eligible for surgery. Eyal Shamir, Chief Executive Officer of IceCure Medical, stated that initiating treatment in the ChoICE Study is a key step in executing the company’s U.S. post-market strategy for ProSense®. Dr. Fine commented that treating the first patient marks an exciting milestone for the ChoICE Study, which is expected to generate additional clinical data supporting cryoablation and help pave the way for broader clinical adoption among appropriately selected breast cancer patients. IceCure Medical develops and markets advanced liquid-nitrogen-based cryoablation therapy systems for the destruction of tumors, with primary focus areas including breast, kidney, bone, and lung cancer. The ProSense® system is marketed and sold worldwide for the indications cleared and approved to date, including in the U.S., Europe, and Asia.

Disagree with this article?